Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 14Metastatic Castration-resistant Prostate Cancer 2Castration Resistant Metastatic Prostate Cancer 2Urologic Neoplasms 1Urologic Diseases 1Neoplasms 1Hypogonadism 1Fatigue 1Eunuchism 1Castration-Resistant Prostate Carcinoma 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 98Fluorouracil 90Capecitabine 86Dexamethasone 81Radiotherapy 80Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Leucovorin 64Drug Therapy 64Cetuximab 60Erlotinib Hydrochloride 56Sorafenib 53atezolizumab 52Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × testosterone 17 beta-cypionate × Clear all
NCT00965341 2016-09-13

Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients

M.D. Anderson Cancer Center

Phase 3 Completed
53 enrolled 8 charts

Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡